



ASX ANNOUNCEMENT

Increase to Private Credit Loan Facility

3 July 2026 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) refers to its announcement of 27 October 2025 in relation to the Company's debt restructure and entry into new loan arrangements with its private credit lender (the **Lender**).

The Company advises that it has agreed with the Lender to increase the total commitment available under the same terms of the existing Private Credit Loan Facility by \$2million, less establishment fees (**Additional Commitment**).

The Additional Commitment may only be drawn to fund specific purposes agreed between the Company and the Lender (each an **Approved Purpose**). The early redemption of the Company's convertible notes (including associated costs) as announced on 30 June 2026, is such an Approved Purpose.

This increase is consistent with the Company's statement in its Quarterly Activities Report (released 29 April 2026) that it was in discussions with its debt provider regarding further funding.

Authorised for release by the Board of Directors, Cann Group Limited.

For all other information please contact:

Mike Ryan
Executive Chairman
Cann Group Limited
+61 3 9095 7088
contact@canngrouplimited.com

Steven Notaro
Company Secretary
Cann Group Limited
+61 3 9095 7088
contact@canngrouplimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company operates a state-of-the-art large-scale cultivation and GMP manufacturing facility, with integrated research capability, near Mildura, Victoria. Through its Botanitech and Mallee Bloom brands, together with bulk and white label, Cann Group supplies a range of dried flower, oil, vape and edible medicinal cannabis products to customers in Australia and around the world.

Learn more at: www.canngrouplimited.com | www.satipharm.com